CALIFORNIA BIOTECHNOLOGY REDUCES LOSS FOR YEARCalifornia Biotechnology Inc. (NASDAQ:CBIO) of Mountain View,Calif., said that at the end of the year it had $32.4 million incash and marketable securities compared with $34.5 million atthe end of 1989.

Fourth quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,967 4,300 -31Operating income (loss) (2,058) (760) -171Net income (loss) (1,208) (861) -46Net income per share (loss) (.10) (.08) -25Outstanding shares 11,695 11,434 +2

Year ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $12,425 12,362 negl.Operating income (loss) (8,398) (8,166) -3Net income (loss) (5,131) (8,217) +38Net income per share (loss) (.44) (.72) +39Outstanding shares 11,591 11,478 +1

BIO-RAD SETS NEW HIGHS IN REVENUES, EARNINGS

Bio-Rad Laboratories Inc. (ASE;BIO.A/BIO.B) of Hercules, Calif.,said it established new highs in sales and earnings for the year.Earnings per share for 1989 were $1.33 before anextraordinary charge of 15 cents per share for costs associatedwith the October 1989 earthquake.

The company said sales were up in all three segments of itsbusiness and that diagnostic products continued to showparticular strength in both sales and operating income. Thecompany also said that the California Superior Court upheld, inpart, the legal basis of its claim for additional compensationfrom the state for Richmond, Calif., properties taken in a 1984eminent domain action. The company expects a jury trial laterthis year.

Fourth quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $80,291 64,809 +24Operating income 7,988 4,473 +79Extraordinary charge 0 1,168 n/aNet income (loss) 3,410 1,692 +101Net income per share (loss) .44 .22 +100Outstanding shares 7,838 7,679 +2

Year ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $286,673 236,271 +21Operating income 24,268 20,998 +16Extraordinary income 0 (1,168) n/aNet income (loss) 10,712 8,981 +19Net income per share (loss) 1.37 1.18 +16Outstanding shares 7,831 7,643 neg.

NEWPORT POSTS FOURTH-QUARTER PROFIT

Newport Pharmaceuticals International Inc. (NASDAQ:NWPH) ofLaguna Hills, Calif., said it took a $1.2 million charge to earningsfor the year resulting from the exchange last April of notes forcommon stock.

Revenues of the company's subsidiary, America's PharmacyInc., which now represent about 86 percent of the parentcompany's business, increased by 58 percent to $14.8 million inthe fourth quarter and by 74 percent to $52 million for theyear, compared with the same periods the previous year.

Fourth quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $16,800 11,263 +49Operating income (loss) 201 (524) n/aNet income (loss) 3 (939) n/aNet income per share (loss) 0 (.08) n/aOutstanding shares 12,348 11,423 +8

Fiscal year ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $60,409 39,022 +55Operating income (loss) (325) (861) +62Net income (loss) (2,574) (1,450) -78Net income per share (loss) (.22) (.14) -57Outstanding shares 12,132 11,398 +6

MERIDIAN REVENUES UP, EARNINGS FLAT

Meridian Diagnostics Inc. (NASDAQ:KITS) of Cincinnati said, thatfirst-quarter operating expenses were higher than normal dueto increased promotion and advertising outlays for newproducts

Operating income is expected to improve during the remainderof fiscal 1991, said Jerry L. Ruyan, president and chiefoperating officer

First quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,254 1,690 +33Operating income 161 106 +52Net income (loss) 136 128 +6Net income per share (loss) .03 .03 n.c.Outstanding shares 4,800 4,800 n.c.

ICN EARNINGS DOWN FOR QUARTER, UP FOR YEAR

ICN Biomedicals Inc. (ASE:BIM) of Costa Mesa, Calif., attributedits strong operating performance for the year to significantexpansion of international operations, particularly in WesternEurope, which accounted for 52 percent of 1990 sales. Duringthe year, the company expanded established North Americanproducts -- immunobiologicals, radiochemicals andbiochemicals -- into Europe.

The gross profit margin for products previously marketed byFlow Laboratories, acquired by ICN Biomedicals last November,increased to 49 percent from 38 percent in 1989, the companysaid.

Fourth quarter ended Nov. 30(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $31,854 20,814 +53Extraordinary income 0 67 n.a.Net income (loss) 1,312 1,794 -27Net income per share (loss) .12 .17 -29Outstanding shares 11,276 10,742 +5

Year ended Nov. 30(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $131,259 61,442 +114Extraordinary income 0 506 n/aNet income (loss) 6,802 6,147 +11Net income per share (loss) .80 .57 +29Outstanding shares 10,963 10,697 +2

(c) 1997 American Health Consultants. All rights reserved.

No Comments